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The present study investigated the association of the non-steroidal anti-inflammatory drug ibuprofen 
with itraconazole, fluconazole and amphotericin B against Cryptococcus neoformans isolates. The 
minimal inhibitory concentration (MIC) was found according to M27-A3 protocol and in vitro 
interactions were evaluated using checkerboard microdilution method. Synergism was demonstrated 
between azoles and ibuprofen for most isolates. However, no synergistic effects were seen when 
amphotericin B was combined with ibuprofen. Therefore, our results suggest that ibuprofen presents 
clinical potential when combined with azole drugs in the treatment of cryptococcosis.
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INTRODUCTION
Opportunistic pathogenic fungi such as Candida, 
Aspergillus and Cryptococcus species are responsible for 
systemic infections affecting mainly immunodeficient 
patients such as neonates, transplanted and patients 
with acquired immunodeficiency syndrome (AIDS) 
(Grimaldi et al., 2010). Cryptococcosis is an infection 
mainly caused by encapsulated yeast fungus such as 
Cryptococcus neoformans. This microorganism is found 
in bird droppings and contaminated soil with higher 
prevalence in tropical and subtropical regions (Ramos-
e-Silva et al., 2012). It has the airway as portal of entry 
causing pulmonary infection and can be disseminated 
to the brain resulting in severe meningoencephalitis 
(Prates et al., 2013; Chen et al., 2015). It is estimated that 
cryptococcal meningitis result in 120.000 to 240.000 
deaths per year worldwide (Rajasingham et al., 2017).
The classical treatment of cryptococcosis is 
based on amphotericin B alone or combined with 
5-fluorocytosine or azoles (Reichert-Lima et al. 
2016; Rossato et al., 2016). However, amphotericin B 
formulations have restricted use due to nephrotoxicity 
problems and must be administered by intravenous 
infusion (Kagan et al., 2012; Xie et al., 2014; Lai et al., 
2016); and 5-flucytosine is expensive and is not present 
in therapeutic protocols in several countries, making 
this combination difficult to administer, particularly 
in resource-poor settings (Smith et al., 2015; Lai et al., 
2016). Fluconazole is cheap, safe, and easy to administer 
and is the drug of choice in maintenance therapy, 
typically after cerebrospinal fluid cultures are negative 
(Lai et al., 2016). Nonetheless, fluconazole monotherapy 
is not recommended because it has shown ineffectiveness 
due development of resistant strains (Gullo et al., 2013). 
Ttriazoles voriconazole and posaconazole are highly 
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active in vitro but have unpredictable bioavailability 
and experience with their use for cryptococcosis is still 
lacking. Furthermore, echinocandins, has no useful 
activity against Cryptococcus (Chen et al., 2012). Thus, 
mortality remains high and there are still considerable 
rates of permanent neurological sequels including 
seizures, headache, memory loss, blindness, and 
personality disorders (Chen et al., 2012; Lai et al., 2016).
Currently few antifungals are commercially 
available and the development of new drugs does not 
accompany the high incidence of the development of 
resistant strains and the market needs (Liu et al., 2014). 
Combination therapy with two or more antifungals 
has the potential to reduce antifungal resistance 
and decrease toxicity of each drug, but its side 
effects should be evaluated with caution (Hatipoglu, 
Hatipoglu, 2013). Thus, in vitro association studies 
with non-antifungal agents and antifungal drugs have 
been performed and are still required to delineate in 
vivo assays and consequent clinical trials (Venturini et 
al., 2011; Hatipoglu, Hatipoglu, 2013). Ibuprofen is a 
non-steroidal anti-inflammatory drug commonly used 
for its antipyretic, analgesic, and anti-inflammatory 
effects (Arai, Sugita, Nishikawa, 2005). Ibuprofen 
inhibits inflammation by suppressing cyclooxygenase 
1 and 2 (COX-1 and COX-2) activity with subsequent 
inhibition of prostaglandin (PG) synthesis (Matos, 
Jordan, 2015). Ibuprofen is easily accessible because 
it is inexpensive and has shown synergistic effect 
when combined with fluconazole in Candida strains 
(Hatipoglu, Hatipoglu, 2013; Liu et al., 2014). So, the 
present study aims to test the association of ibuprofen 
with itraconazole, fluconazole and amphotericin B 
against C. neoformans isolates.
MATERIAL AND METHODS
Fungal strains
A total of twenty five clinical isolates of C. neoformans 
isolated from cerebrospinal fluid were included in this 
study. All isolates were previously confirmed by PCR 
(Polymerase Chain Reaction) using primers CNa-70S 
(5’-ATTGCGTCCACCAAGGAGCTC-3’) and CNa-70A 
(5’-ATTGCGTCCATGTTACGTGGC-3’). The isolates 
were provided by the Clinical Analysis Department 
of the Federal University of Rio Grande do Sul, Porto 
Alegre, RS. All isolates were grown on Sabouraud 
dextrose agar at 35 ° C for 48 h prior to the experiments.
Drugs
The drugs were prepared according to Clinical and 
Laboratory Standards Institute (CLSI) recommendations. 
Fluconazole (FLC) stock solution (Metrochem Api 
Private Limited, India) was prepared in distilled water. 
Ibuprofen (IBP; Sigma-Aldrich, USA), itraconazole 
(ITC; MetrochemApi Private Limited), and amphotericin 
B (AMB; MetrochemApi Private Limited) stock solution 
were prepared in dimethylsulfoxide (DMSO; Nuclear, 
Brazil). For the experiments, the compounds were 
diluted in Roswell Park Memorial Institute 1640 medium 
(RPMI 1640; Sigma-Aldrich) to obtain a maximum 
concentration of 2% DMSO.
Antifungal susceptibility testing
Minimum inhibitory concentrations (MICs) of IBP 
and antifungal agents were determined in duplicate by 
the broth microdilution method according to M27-A3 
protocol (CLSI, 2008). Serial two-fold dilutions were 
made in RPMI 1640 medium (Sigma-Aldrich) buffered 
with morpholinepropansulfonic acid (MOPS; Sigma-
Aldrich) and concentrations’ ranges tested were: 0.0312 
- 16 µg/mL of ITC, 0.125 - 64 µg/mL of FLC, 0.0312 
- 16 µg/mL of AMB and 1 - 512 µg/mL of IBP. The 
experiments were carried out in duplicate. MICs values 
were defined as the lowest concentration of compounds 
at which the microorganisms tested did not show visible 
growth (AMB) or reduced 50% of visible growth (FLC, 
IBP and ITC) in 72 h. 
Checkerboard assay
The interaction between IBP and each antifungal 
was evaluated for eight randomly selected C. 
neoformans isolates using the checkerboard method 
(Johnson et al., 2004). The assay lead to forty nine 
different concentration combinations between IBP 
and antifungal agents in concentrations of MIC/8, 
MIC/4, MIC/2, MIC, MICx2, MICx4 and MICx8. The 
experiments were conducted in duplicate and incubated 
at 35°C for 72 h. The effect of the combinations was 
classified by determining the fractional inhibitory 
concentration index (FICI) expressed as the sum of the 
fractional inhibitory concentrations (FIC), as defined by 
the following equation:
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FICA + FICB = MICa in combination MICA tested 
alone + MICB in combination MICBtested alone
where MICA and MICB are the MICs of ibuprofen and 
antifungal agent, respectively (Mukherjee et al., 2005). 
Synersgim was defined when FICI ≤ 0.5, indifference 
when 0.5 < FICI ≤ 4 and antagonism when FICI > 4 
(Odds, 2003).
RESULTS AND DISCUSSION
MIC values of each antifungal agents against 
twenty-five C. neoformans isolates were determined. 
MIC range, Geometric means (GM), MIC50 (MIC 
value which inhibits 50% of the isolates) and MIC90 
(MIC value that inhibits 90% of the isolates) for 
itraconazole (ITC), fluconazole (FLC), amphotericin 
B (AMB) and ibuprofen (IBP) are presented in Table 
I. Standardizations of susceptibility tests for C. 
neoformans are less developed than for Candida spp.; so 
that, there are no breakpoints established. The isolates 
showed variable susceptibility to antifungal agents and 
isolates with low sensitivity were found. The isolates 
showed low MICs range for ITC (0.03125 – 1 µg/mL) 
compared to FLC (0.25 – 8 µg/mL) and AMB 
(0.5 – 16 µg/mL). The geometric mean of MIC was also 
lower for ITC (0.66 µg/mL) than for FLC (1.74 µg/mL) 
and AMB (6.17 µg/mL). Since IBP is not an antifungal 
and there is no standardization in relation to the 
evaluation of its inhibitory effect, we consider as MIC 
the concentration that reduces 50% fungal growth. 
Based on the high MICs, the non-antifungal agent 
showed weak antifungal activity against C. neoformans.
Table II presents the effects of antifungal agent 
combination, which demonstrated synergism or 
indifference. The combination of azoles (ITC and 
FLC) with IBP resulted predominantly in synergism, 
which was detected in 75% of isolates for combination 
with FLC and in 62% of isolates for combination with 
ITC. On the other hand, AMB associated with IBP 
resulted in 100% of indifference against C. neoformans. 
Antagonism was not detected against both groups. MIC 
for AMB combined with IBP was chosen when fungal 
growth was reduced in 100%.
The limited efficacy and the difficulty to introduce 
new antifungal drugs into the market make the drugs 
association an important therapeutic strategy to treat 
potentially life-threatening invasive fungal infections 
(Fuentefria et al., 2018). Previous studies have detected 
synergism between IBP and azole against C. albicans 
(Ricardo et al., 2009; Costa-de-Oliveira et al., 2015; 
Sharma et al., 2015) and C. neoformans (Ogundeji, 
Pohl, Sebolai, 2016) increasing the susceptibility of the 
isolates to these antifungal agents, and corroborating 
with research. Other non-steroidal anti-inflammatory 
drugs, such as tenoxicam, diclofenac sodium and 
sodium salicylate have also shown synergistic effect 
when combined with azoles (Yücesoy, Oktem, Güllay, 
2000). However, studies are commonly performed with 
Candida species.
Several mechanisms may be involved in the 
selection of azole resistant strains, such as mutations 
causing structural changes in enzyme affinity, 
overproduction of enzymes and overexpression of 
efflux pumps (Gullo et al., 2013). Efflux pumps are 
transporter proteins present in the plasma membrane 
and are involved in the removal of azoles from the 
cytoplasm. When efflux pumps are overexpressed there 
is expulsion of the drug out of the cell reducing the drug 
concentration at the action site. These mechanisms are 
responsible for Cryptococcus resistance against most 
azoles (Basso Jr et al., 2015). 
TABLE I - Susceptibility profile of twenty five isolates of 
Cryptococcus neoformans to antifungal agents. Rresults 
were expressed in ranges of variation of minimum 
inhibitory concentrations values (MIC ranges), geometric 
mean (GM) of 25 isolates, MIC50 (MIC value that inhibits 
50% of the isolates) and MIC90 (MIC value that inhibits 














0.03125 - 1 0.66 1 1
Fluconazole 
(FLC)
0.25 – 8 1.74 2 4
Amphotericin 
B (AMB)
0.5 – 16 6.17 4 16
Ibuprofen (IBP) 128 - 512 319.57 256 512
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TABLE II - In vitro susceptibility of Cryptococcus neoformans to ibuprofen (IBR) combined with itraconazole (ITC), fluconazole 









IBP FLC ITC AMB IBP FLC FICI Interaction IBP ITC FICI Interaction IBP AMB FICI Interaction
CN06 512 4 0.25 2 8 1 0.26 Syn 256 0.0625 0.5 Syn 8 2 1.01 Ind
CN07 512 8 0.5 2 128 0.25 0.25 Syn 8 0.25 0.52 Ind 16 2 1.03 Ind
CN10 512 2 0.25 2 64 0.5 0.375 Syn 64 0.03125 0.25 Syn 512 1 1.5 Ind
CN11 512 4 0.5 4 8 2 0.52 Ind 16 0.125 0.28 Syn 256 2 1 Ind
CN17 512 4 0.25 0.5 8 1 0.27 Syn 8 0.125 0.52 Ind 256 0.25 1 Ind
CN19 512 4 0.5 2 64 1 0.38 Syn 8 0.125 0.27 Syn 512 1 1.5 Ind
CN24 256 4 0.25 4 4 1 0.26 Syn 64 0.125 0.75 Ind 512 2 2.5 Ind
CN25 512 2 0.25 2 256 0.5 0.75 Ind 128 0.0625 0.5 Syn 256 0.25 0.63 Ind
Syn = Synergism
Ind = Indifferent
Understanding the resistance mechanisms of azoles 
and the action of IBP helps to explain our findings of in 
vitro synergy. IBP is an efflux pump blocker and can 
prevent the output of azole from the fungal cell. Thus, 
the high susceptibility of cells to IBP + azoles association 
may be attributed to the increase in intracellular 
concentration of the antifungal (Pina-Vaz et al., 2005). 
On the other hand, AMB does not require internalization 
into fungal cells for exerting their antifungal activity and 
so they escape from efflux systems (Vandeputte, Ferrari, 
Coste, 2012). This may justify the indifferent effect of 
IBP + AMB association found in the present study. 
Besides, previous studies showed that IBP causes 
fungal membrane damage and can be considered, 
depending on the dose, fungicide or fungistatic (Argenta 
et al., 2012; Arai, Sugita, Nishikawa, 2005). Our results 
corroborate these studies, since IBP alone was able to 
inhibit cell growth of C. neoformans isolates. The anti-
inflammatory effect of IBP can also be relevant in the 
treatment of fungal infections, since prostaglandins 
may be involved in fungal colonization’s and its anti-
inflammatory mechanism works mostly by inhibiting 
cyclooxygenase isoenzymes (Rusu et al., 2014). 
In addition to the advantageous effects mentioned 
above, IBP has a good record of efficacy and safety, 
and thus it is the most commonly used nonsteroidal 
anti-inflammatory drug. It can be used even for the 
most vulnerable patient populations. Furthermore, 
pharmacokinetic studies of ibuprofen showed that it 
penetrates into the cerebrospinal fluid, which may be 
advantageous in treatments of cryptococcal meningitis 
(Bannwarth et al., 1995; Kokki et al., 2007). Thus, IBP 
may improve the action of azoles and may still present 
clinical benefits due to anti-inflammatory action and its 
favorable pharmacokinetics.
CONCLUSION
The results of this present study suggest that 
the combination of IBP and azole drugs may be 
suitable for cryptococcosis therapy since synergism 
was demonstrated. Further in vivo studies in clinical 
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situations are still required to prove the effects of the 
combination of ibuprofen and azoles antifungals.
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